
treks1

three prime repire exonucles 1 ennathu manushyaril "treks 1" jeane encode cheiyunna oru ensaimaanu.
pravartthanam.
eee jeane manushyakoshangalile pradhana 3 '-> 5' dna exonuclesine encode cheiyunnu. protein oru prosess cheyyaatha exonucles aanu, athu oru manushya dna polymerasinu oru proof reeding pravartthanam nalkum. ithu settu complexinte oru ghadakam koodiyaanu, koodaathe gransime eiii-mediated sell deth samayat nick cheytha dnaude 3 'attangal athivegam tharamthaazhthunnathinu pravartthikkunnu. eee jeenile mutationukal icardy-gauttiyars syndrome, chilblane lupus, arvcl (cerebral leukodistrophy rettina vasculopathy), kree encephalitis ennivaykku kaaranamaakunnu. eee jeeninaayi vyathyastha isophomukal encode cheiyunna onniladhikam traanskript vakabhedangal kandethiyittundu.
klinikkal prasakthi.
treks 1" jeeninullile mutationukal familial chilblane lupessinu kaaranamaakunnu. treks 1" polymorphisangal systemic lupus erithamattosasinu saadhyatha nalkunnu. treks 1" jeeninte missense mutationukal athinte exonucleolytic seshiye ganyamaayi kuraykkukayum nucleic aasidukalude shekharanathinu kaaranamaakukayum cheiyunnu. cytoplaasathinakathu nucleic aasidukalude nirmmaanam oottoo immyoon prathikaranangalkk kaaranamakunna type-aii interferon prathikaranangale uthejippikkunnu. aduthide nadanna oru genome wide association padanatthil "treks 1" jeane (<aii. dii. 1>) adangiyirikkunna pradesham covid-19 theevrathayumaayi bandhappettirikkunnu. saars-cove-2 baadhicha rogikalil chilblain polulla murivukal undaakunnathine ithu vishadeekarichekkaam.
cytoplaasathile vairal cdna tharamthaazhthunnathiloode cytosolic sensing ozhivakkaan treks 1 echuaivi-1 neey sahayikkunnu.
treks 1 leeii mutationukal dnal thettayi incorporate cheytha raibo nucleodideukale uchithamayi neekkam cheiyunnathil paraajayappedaan kaaranamakum. rebonucleotide exision repire vazhiyaan neekkam cheyyal prakriya nadathunnathu. manushyaril, eee prakriyayile oru vaikalyam microsephaly, neuro inflammation enniva ulppedunna icardy-gauttiyars syndrome undaakkum.

